Associated Papers
Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.
Braun F et al.
The Journal of Clinical Investigation, 2023
37014703 (PubMed )
Supplement: jci-133-157782-s180.xlsx › Table_S1
Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.
Najafian B et al.
Journal of the American Society of Nephrology : Jasn, 2020
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Germain DP et al.
Journal of Medical Genetics, 2015
25795794 (PubMed )
Supplement: jmedgenet-2014-102797-s1.pdf
Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative.
Sirrs S et al.
Molecular Genetics and Metabolism, 2010
Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype.
Ashley GA et al.
Journal of Human Genetics, 2001
Select a paper to view details